Overview

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy, safety and tolerability of 12-weeks treatment with darifenacin in patients aged >Ý 65 years with OAB.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Collaborator:
Procter and Gamble
Treatments:
Darifenacin